Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2021 06:00 ET | Source: CytoDyn Inc.

CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research

All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER,...
September 13, 2021 06:00 ET | Source: CytoDyn Inc.

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
September 09, 2021 20:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...
September 02, 2021 18:40 ET | Source: CytoDyn Inc.

CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
August 26, 2021 17:02 ET | Source: CytoDyn Inc.

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led...
August 25, 2021 08:00 ET | Source: CytoDyn Inc.

CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS CytoDyn plans to update its Breakthrough Therapy...
August 13, 2021 06:00 ET | Source: CytoDyn Inc.

CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report

Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will Be Fully Resubmitted as Early as September 2021 VANCOUVER,...
July 19, 2021 16:41 ET | Source: CytoDyn Inc.

CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
July 19, 2021 06:00 ET | Source: CytoDyn Inc.

CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
July 12, 2021 06:00 ET | Source: CytoDyn Inc.

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks VANCOUVER, Washington, July 12, 2021 (GLOBE...